Clopidogrel-Induced Neutropenia after Coronary Stenting: Is Cilostazol a Good Alternative?
Author Information
Author(s): Massimo Montalto, Italo Porto, Antonella Gallo, Claudia Camaioni, Roberta Della Bona, Antonio Grieco, Filippo Crea, Raffaele Landolfi
Primary Institution: Catholic University of Rome
Hypothesis
Can cilostazol be an effective alternative treatment for patients experiencing clopidogrel-induced neutropenia after coronary stenting?
Conclusion
Cilostazol may be a safe and effective alternative to clopidogrel for patients who develop neutropenia after coronary stenting.
Supporting Evidence
- Clopidogrel can cause severe neutropenia, a rare but serious side effect.
- The patient showed improvement after switching from clopidogrel to cilostazol.
- Cilostazol is commonly used for managing peripheral arterial disease.
Takeaway
If someone has a bad reaction to a heart medicine called clopidogrel, another medicine called cilostazol might help them feel better without causing more problems.
Methodology
A case report of a 65-year-old male patient who developed severe neutropenia after clopidogrel treatment following coronary stenting, treated with cilostazol.
Potential Biases
Potential bias due to the lack of a control group and reliance on a single patient's outcome.
Limitations
The findings are based on a single case report, limiting generalizability.
Participant Demographics
65-year-old Caucasian male with untreated hypertension and smoker status.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website